Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions.
A nonapeptide (16L1) was derived from the human papillomavirus type 16 (HPV-16) major capsid protein and tested for detection of potential cross-reactive serum IgG and cervical IgA antibodies in low- and high-risk HPV-associated low-grade squamous intraepithelial lesions (LSIL) and cervical cancer patients by ELISA. The IgG response was similar in women with low-risk HPV-associated LSIL and controls (P=0.1). In contrast, more than 90 % of patients with high-risk HPV-associated LSIL were seropositive. Although tumours from cancer patients were all positive for the presence of high-risk HPV DNA, the level of seropositivity decreased significantly in this group (P<0.0001). Cervical IgA antibodies were also detected in a significantly high proportion of women with high-risk HPV-associated LSIL compared with controls. However, the proportion of IgA-positive patients was lower than the proportion of IgG seropositives. In conclusion, the 16L1 peptide appears to be a high-risk type-common epitope that induces cross-reactive antibodies in high-risk, but not low-risk, HPV-associated LSIL patients, allowing differentiation of high- and low-risk infected women at this stage of infection.
Department of Molecular Biology and Biotechnology, Institute of Biomedical Research, National University of Mexico, Circuito Escolar S/N, Cd Universitaria, Apdo Postal 70228, DF CP 04510 Mexico City, Mexico.
Leticia
L
Rocha-Zavaleta
Department of Molecular Biology and Biotechnology, Institute of Biomedical Research, National University of Mexico, Circuito Escolar S/N, Cd Universitaria, Apdo Postal 70228, DF CP 04510 Mexico City, Mexico.
Juana P
JP
Ambrosio
Laboratory of Immunobiology (L-326), Unit of Research on Cellular Differentiation and Cancer, FES Zaragoza, National University of Mexico, Mexico City, Mexico.
Maria de Lourdes
ML
Mora-Garcia
National Center for Clinics of Dysplasias (CENACLID), General Hospital of Mexico, Mexico City, Mexico.
Fernando
F
Cruz-Talonia
Laboratory of Immunobiology (L-326), Unit of Research on Cellular Differentiation and Cancer, FES Zaragoza, National University of Mexico, Mexico City, Mexico.
Jorge
J
Hernandez-Montes
Laboratory of Immunobiology (L-326), Unit of Research on Cellular Differentiation and Cancer, FES Zaragoza, National University of Mexico, Mexico City, Mexico.
Benny
B
Weiss-Steider
Unit of Molecular Biomedicine, CINVESTAV, IPN, Mexico City, Mexico.
Vianney
V
Ortiz-Navarrete
Laboratory of Immunobiology (L-326), Unit of Research on Cellular Differentiation and Cancer, FES Zaragoza, National University of Mexico, Mexico City, Mexico.
Alberto
A
Monroy-Garcia
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D036022:Capsid Proteins / Q000276:immunology*; D002584:Cervix Uteri / Q000276:immunology / Q000378:metabolism; D004279:DNA, Viral / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000276:immunology*; D027383:Papillomaviridae / Q000145:classification / Q000276:immunology* / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D016133:Polymerase Chain Reaction; D012307:Risk Factors; D012680:Sensitivity and Specificity; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D002578:Uterine Cervical Dysplasia / Q000097:blood / Q000175:diagnosis* / Q000276:immunology
D000914:Antibodies, Viral; D014408:Biomarkers, Tumor; D036022:Capsid Proteins; D004279:DNA, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D009856:Oncogene Proteins, Viral; C063317:L1 protein, Human papillomavirus type 16